Robert W. Baird initiated coverage of Renovacor with a rating of Outperform and set a new price target of $9.00

Ladenburg Thalmann initiated coverage of Renovacor with a rating of Buy and set a new price target of $22.00

Chardan Capital Markets initiated coverage of Renovacor with a rating of Buy and set a new price target of $20.00

Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies Renovacor, Inc. (NYSE:RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations. "With Kumar's appointment, we've added yet another innovative industry expert to Renovacor's diverse and growing leadership team," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. "Kumar is

Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice Renovacor, Inc. (NYSE:RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. "We are excited to welcome Jordan to Renovacor's leadership team during this pivotal time for the company," said Magdalene Cook, M.D., Chief Executive Officer of Renovacor.

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

4 - Renovacor, Inc. (0001799850) (Issuer)

Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"

Acquisition further extends Rocket's leadership in AAV-based cardiac gene therapy and expands focus and capabilities to BAG3-associated dilated cardiomyopathy Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that it has completed the previously announced acquisition of Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Under the terms of t

Acquisition further strengthens Rocket's leadership in AAV-based cardiac gene therapy and expands Company's near-term clinical assets for the treatment of heart conditions Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 di

Research collaboration with the University of Utah's Nora Eccles Harrison Cardiovascular Research and Training Institute expands pipeline with the addition of an AAV gene therapy program for multiple genetic segments of arrhythmogenic cardiomyopathy Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program,

REN-001 advancing toward IND submission in the second half of 2022 with the initiation of a Phase I/II clinical trial in BAG3-DCM expected thereafter Strengthened executive team with appointment of Fred Driscoll as CFO Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the first quarter of 2022 and provided a corporate update. "Our first quarter progress was highlighted by REN-001's continued advancement towards the clinic and by the addition of industry veteran Fred Drisc

Mr. Driscoll has over 25 years of biotech executive experience and most recently served as the CFO of Flexion Therapeutics through its sale to Pacira BioSciences for up to $1 billion Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced the appointment of Fred Driscoll as Chief Financial Officer (CFO). "Fred has a wealth of experience guiding financial strategy for publicly-traded biotech companies and we are thrilled to welcome him to Renovacor," said Magdalene Cook, M.D., Chief Executive Officer

Debuted as a public company and raised gross proceeds of $95.1 million from the business combination with Chardan Healthcare Acquisition 2 Corp and a concurrent PIPE financing Strengthened company leadership with key appointments including Marc Semigran, M.D., as CMO, Matthew Killeen, Ph.D., as CSO and Elizabeth White, Ph.D., as CBO and SVP of Operations Reported topline preclinical data demonstrating successful cardiac transduction with REN-001 delivered via local infusion at a low vector dose in a pilot pig study Significant progress made across key ongoing REN-001 IND-enabling studies IND submission for REN-001 is expected in the second half of 2022 with the initiation of a Phase I/I

Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that Magdalene Cook, M.D., Chief Executive Officer, will present a corporate overview at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 9:10 a.m. ET. A webcast of the presentation will be available by visiting the Investors and Media section of Renovacor's website under "Events and Presentations." A replay of the webcast will be available on the Renovacor website for 30 days following the conference. About Renovacor

Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN). The company will provide sponsorship for initiatives to raise awareness of cardiomyopathies and to educate the patient and provider communities about the importance of genetic testing for patients and families living with DCM. "We are proud to be partnering with three great organ

Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, today announced that Magdalene Cook, M.D., President and Chief Executive Officer of Renovacor, will participate in a panel presentation at the 11th Annual LifeSci Partners Corporate Access Event. Details on the panel are shown below: Title: Gene Therapy: Reaching its Full Potential Date: Thursday, January 6, 2022 Time: 11:00 a.m. ET Webcast Link: https://wsw.com/webcast/lifesci3/panel8/2389200 A replay of the panel presentation will be available by visiting the Investors and

Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023. Under the terms of the agreement, Rocket Pharmaceuticals has agreed to give Renovacor $53.00 million in stock in exchange for RCOR stock. About The Companies Involved Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its t

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter. For Aurora Cannabis Inc (NASDAQ:ACB), Canaccord Genuity upgraded the previous rating of Sell to Hold. For the fourth quarter, Aurora Cannabis had an EPS of $0.00, compared to year-ago quarter EPS of $0.55. At the moment, the stock has a 52-week-high of $6.05 and a 52-week-low of $1.21. Aurora Cannabis closed at $1.40 at the end of the last trading period. According to Exane BNP Paribas, the prior rating for TechnipFMC PLC (NYSE:FTI) was changed from Neutral to Outperform. In the s

BTIG analyst Yun Zhong downgrades Renovacor (AMEX:RCOR) from Buy to Neutral.

Gainers SOBR Safe, Inc. (NASDAQ:SOBR) shares surged 232.8% to settle at $3.03 on Tuesday following a report suggesting The National Transportation Safety Board is recommending that NHTSA require passive alcohol-detection systems. The company is engaged in developing alcohol-detecting devices to address the automotive alcohol sensing spectrum. Amprius Technologies, Inc. (NYSE:AMPX) shares jumped 86.4% to close at $11.00 on Tuesday. Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) surged 60.6% to settle at $2.2005. NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) gained 42.4% to close at $20.79. Strength may be due to short interest in the stock and social media interest. Virax Biolabs Group

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping 400 points on Tuesday. The Dow traded down 1.3% to 30,620 while the NASDAQ fell 1.05% to 11,414.46. The S&P 500 also fell, dropping, 1.29% to 3,849.76. Also check this: Volatility In Markets Declines Ahead Of Fed's Policy Meeting Leading and Lagging Sectors Energy shares fell by just 0.9% on Tuesday. Meanwhile, top gainers in the sector included DMC Global Inc. (NASDAQ:BOOM), up 7% and PBF Energy Inc. (NYSE:PBF) up 5%. In trading on Tuesday, real estate shares dipped by 3%. Top Headline Housing starts in the US surged 12.2% month-over-month to an annualized rate of 1.575 million units in August, wh

Gainers Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares jumped 51% to $0.4957. Crown ElectroKinetics, last month, posted a Q4 net loss of $4.5 million. Virax Biolabs Group Limited (NASDAQ:VRAX) gained 47.7% to $3.6493 after the company announced the distribution of a Monkeypox Virus Antigen Rapid Test Kits which has been launched in markets accepting the CE mark, such as the European Union. BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) shares gained 25.8% to $6.92. BYND Cannasoft shares jumped over 32% on Monday after the company announced it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments for $28 million in stock. TRxADE HEAL

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.99% to 30,713.87 while the NASDAQ fell 0.50% to 11,477.13. The S&P 500 also fell, dropping, 0.92% to 3,863.94. Also check this: Volatility In Markets Declines Ahead Of Fed's Policy Meeting Leading and Lagging Sectors Information technology shares fell by just 0.3% on Tuesday. Meanwhile, top gainers in the sector included BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN), up 13% and Innoviz Technologies Ltd. (NASDAQ:INVZ) up 10%. In trading on Tuesday, real estate shares dipped by 1.9%. Top Headline Housing starts in the US surged 12.2% month-over-m

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has agreed to acquire Renovacor Inc (NYSE:RCOR) in an all-stock transaction for an implied value of approximately $2.60 per share. The transaction is currently expected to close by the first quarter of 2023. "The acquisition of Renovacor aligns with our strategy to expand our leadership position in AAV-based gene therapy for cardiac disease and gives us a perfect opportunity to continue on our mission to transform the lives of heart failure patients through the power of gene therapy," said Gaurav Shah, CEO of Rocket.  Renovacor's most advanced program, REN-001, is an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, and Renovacor, Inc. (NYSE:RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced a definitive agreement under which Rocket will acquire Renovacor in an all-stock transaction for an implied value of approximately $2.60 per share, based on the volume weighted average trading price of Rocket shares of $15.51 for

Gainers AMTD Digital Inc. (NYSE:HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news. Avenue Therapeutics, Inc. (NASDAQ:ATXI) surged 53.2% to close at $0.3562. AMTD IDEA Group (NYSE:AMTD) surged 50% to close at $1.95 on Wednesday. Aileron Therapeutics, Inc. (NASDAQ:ALRN) rose 42.2% to settle at $0.2702. Aileron Therapeutics, last month, posted a Q2 loss of $0.09 per share. Dawson Geophysical Company (NASDAQ:DWSN) gained 40.2% to close at $1.57. Akerna Corp. (NASDAQ:KERN) shares gained 26.9% to close at $0.1650 on Wednesday after gaining 8% on Tuesday. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM